Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman

Provided By PR Newswire

Last update: Nov 7, 2025

SLNO Investors with Losses Encouraged to Contact Hagens Berman

SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing information about VYKAT™ XR, a once-daily oral tablet intended to treat hyperphagia. Soleno has described this condition as "the most life-limiting aspect" of Prader-Willi syndrome, a rare genetic disorder that causes physical, mental, and behavioral problems.